Article

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer

2023-09-27

Abstract excerpt

<h4>Background: </h4> and Purpose: Drug repurposing has potential to improve the care for treatment resistant high-grade serous ovarian cancer (HGSOC). We hypothesised that broadly targeting PARP for drug repurposing would elicit cytotoxic responses in HGSOC through multiple biological processes. Experimental Approach: in-silico ligand-based virtual screening BLAZE was used to identify drugs with potential PARP-bi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 25cba75d-3dd1-57e8-b291-e5e834db6cd4
DOI: 10.22541/au.169580899.90269470/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerDOI 10.22541/au.169580899.90269470/v1Read

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair PathwaySemantic proximity Read

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapySemantic proximity Read

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancerSemantic proximity Read

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer modelsSemantic proximity Read

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic TargetingSemantic proximity Read

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.Semantic proximity Read

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancerSemantic proximity Read

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.Semantic proximity Read

Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responsesSemantic proximity Read

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read